 | | Vol. 11.42 – 27 October, 2020 |
| |
|
|
| Scientists demonstrated that resistance to venetoclax with azacitidine occurred via upregulation of fatty acid oxidation, which occurs either due to RAS pathway mutations or as a compensatory adaptation in relapsed disease.
[Nature Cancer] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Understanding of the processes that drive transformation of certain clones to cancer is limited. The authors studied this phenomenon in the context of clonal hematopoiesis and the development of therapy-related myeloid neoplasms.
[Nature Genetics] |
|
|
|
| Researchers showed that mitochondrial membrane potential could be used to prospectively isolate chronologically old HSCs with transcriptional features and functional attributes characteristic of young HSCs, including a high rate of transcription and balanced lineage-affiliated programs.
[Cell Stem Cell] |
|
|
|
| In 290 normal subjects from the GeneSTAR Research Study, investigators generated whole genome sequence data from whole blood and RNA sequence data from extracted non-ribosomal RNA from 185 induced pluripotent stem cell-derived megakaryocyte cell lines and 290 blood platelet samples from these subjects.
[Blood] |
|
|
|
| Scientists employed a cellular model of murine multipotent hematopoietic progenitors to knock out 39 transcription factors followed by RNA‐Seq analysis, to functionally define a regulatory network of 16,992 regulator/target gene links.
[EMBO Journal] |
|
|
|
| Researchers showed that large invaginations were generated by microtubule constraints on the swelling nucleus of human hematopoietic stem and progenitor cells during early commitment toward the myeloid lineage.
[EMBO Journal] |
|
|
|
| To target acute myeloid leukemia blasts and leukemic stem cells using natural killer (NK) cells, scientists developed a trispecific killer engager molecule containing a humanized anti-CD16 heavy chain camelid single-domain antibody that activated NK cells.
[Leukemia] |
|
|
|
| Using a recently developed specific inhibitor, the authors found that vacuolar protein sorting 34 inhibition induced apoptosis in acute myeloid leukemia cells but not in normal CD34+ hematopoietic cells.
[Oncogenesis] |
|
|
|
| Scientists examined the expression of ACE2, to which SARS-CoV-2 Spike protein binds to facilitate viral entry, in cord blood derived hematopoietic stem cells/hematopoietic progenitor cells and in peripheral blood derived immune cell subtypes.
[Stem Cell Reviews and Reports] |
| |
|
|
| The authors compared outcomes after treatment with autologous hematopoietic stem cell transplantation and alemtuzumab in patients with relapsing–remitting multiple sclerosis.
[Journal of Neurology Neurosurgery and Psychiatry] |
|
|
|
| Researchers studied 2,528 patients with upfront autologous hematopoietic cell transplantation for multiple myeloma from 2008–2017 to develop a prognostic model to predict outcomes.
[British Journal of Haematology] |
|
|
|
|
| The authors detail the metabolic features of leukemic stem cells (LSCs) and how these characteristics promote resistance to traditional chemotherapy. They also discuss new therapeutic approaches that target metabolic vulnerabilities of LSC to selectively eradicate them.
[Trends in Molecular Medicine] |
|
|
|
| Researchers bring together what is currently known about chromatin status and the development of cells in the hematopoietic system under normal and abnormal conditions.
[Trends in Genetics] |
|
|
|
|
| NexImmune announced that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.
[NexImmune] |
|
|
|
| Keros Therapeutics, Inc. announced that it has dosed the first two participants in a Phase II clinical trial evaluating KER-050 for the treatment of anemia and thrombocytopenia in myelodysplastic syndromes.
[Keros Therapeutics, Inc.] |
|
|
|
| Sumitomo Dainippon Pharma Oncology, Inc. announced the first patient has been dosed in a Phase Ib/II study evaluating the oral investigational agent, dubermatinib, an AXL kinase inhibitor, in combination with decitabine, in patients 60 years or older with newly diagnosed acute myeloid leukemia who have TP53 mutations and/or complex karyotype.
[Sumitomo Dainippon Pharma Oncology, Inc.] |
|
|
|
| EdiGene, Inc. announced the Center for Drug Evaluation of China National Medical Products Administration has accepted for review the company’s Investigational New Drug application for ET-01, autologous CD34+ hematopoietic stem/progenitor cells with the erythroid -specific enhancer of the BCL11A gene modified by CRISPR/Cas9, an investigational gene-editing therapy for patients with transfusion dependent β-thalassemia.
[EdiGene, Inc.] |
|
|
|
|
| January 25 – January 27, 2021
Virtual |
|
|
|
|
|
| | Karolinska Institutet – Flemingsberg, Sweden |
|
|
|
| | University of Navarra – Pamplona, Spain |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | University of Illinois at Chicago – Chicago, Illinois, United States |
|
|
|
| | The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
